Shivalik Rasayan Ltd (SHIVALIK) AI Stock Analysis

• Market Cap: ₹8.90B
• Dividend Yield: 0.09%
• Average Volume (3M): 5.33K
• Price to Earnings (P/E): 58.9
• Beta (1Y): 0.79
• Revenue Growth: 15.29%
• EPS Growth: 25.48%
• Country: IN
• Employees: 267
• Sector: Basic Materials
• Sector Strength: 60
• Industry: Agricultural Inputs
• EPS (TTM): 1.02
• Shares Outstanding: 15,750,365
• 10 Day Avg. Volume: 6,263
• 30 Day Avg. Volume: 5,331
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹602.00
• Price Target Upside: 6.54% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: ₹523.00 ▼(-7.44% Downside)

Shivalik Rasayan Ltd's overall stock score is primarily influenced by its strong revenue growth and solid equity base, which are positive indicators. However, bearish technical indicators and a high P/E ratio suggest caution. The company's cash flow management issues and low dividend yield further contribute to a moderate overall score.

Shivalik Rasayan Ltd Business Overview & Revenue Model

Company Description

Shivalik Rasayan Ltd (SHIVALIK) is an Indian company operating primarily in the chemical sector, with a strong focus on the production of agrochemicals and pharmaceuticals. The company is known for its expertise in manufacturing intermediates and active pharmaceutical ingredients (APIs) that cater to both domestic and international markets. By leveraging advanced technologies and a commitment to quality, SHIVALIK has carved out a niche in the specialty chemicals and pharmaceutical industries.

How the Company Makes Money

Shivalik Rasayan Ltd generates revenue through the manufacturing and sale of agrochemical and pharmaceutical products. The company produces active pharmaceutical ingredients (APIs) and intermediates, which are crucial components in the formulation of various drugs. These products are sold to pharmaceutical companies, both within India and internationally, contributing significantly to its revenue. Additionally, SHIVALIK's presence in the agrochemical sector involves producing chemicals that enhance agricultural productivity, which are sold to farmers and agricultural enterprises. Strategic partnerships and collaborations in research and development further support its revenue growth by allowing the company to innovate and expand its product offerings.

Shivalik Rasayan Ltd Financial Statement Overview

Summary

Shivalik Rasayan Ltd shows strong revenue growth and a solid equity base, but faces challenges with net profit margin volatility and cash flow management. Improving operational efficiency and cash flow will be crucial for financial stability.

Income Statement

Shivalik Rasayan Ltd has shown consistent revenue growth over the years, with a notable increase in total revenue from 2024 to 2025. The gross profit margin has been strong, indicating good cost management. However, the net profit margin has shown some volatility, with a decrease from 2023 to 2025, pointing to increased expenses or lower efficiency in recent years. EBIT and EBITDA margins are relatively stable, supporting operational profitability.

Balance Sheet

The company's balance sheet displays a solid equity position, with stockholders' equity increasing over the years. The debt-to-equity ratio remains manageable, although there has been an increase in total debt from 2023 to 2025. The equity ratio indicates a strong reliance on equity financing, which is a positive sign for stability. However, rising debt levels could pose a risk if not managed properly.

Cash Flow

Shivalik Rasayan Ltd faces challenges in cash flow management, evident from negative operating and free cash flows over recent years. The free cash flow growth rate has been negative, indicating cash outflow issues. The company needs to improve cash flow from operations to ensure better financial health and sustainability.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.12B	2.72B	2.34B	2.15B	1.98B
Gross Profit	805.70M	479.95M	1.20B	931.00M	700.71M
EBITDA	485.11M	431.55M	476.08M	534.26M	411.80M
Net Income	166.96M	127.17M	212.35M	342.52M	256.06M
Balance Sheet
Total Assets	7.34B	6.92B	5.78B	4.88B	3.63B
Cash, Cash Equivalents and Short-Term Investments	279.69M	377.38M	306.71M	707.58M	47.73M
Total Debt	938.83M	859.67M	577.15M	411.22M	301.48M
Total Liabilities	1.98B	1.85B	1.59B	1.24B	1.03B
Stockholders Equity	5.36B	3.90B	3.60B	2.87B	1.79B
Cash Flow
Free Cash Flow	-294.37M	-757.31M	-821.81M	-138.32M	-64.92M
Operating Cash Flow	-86.05M	-80.75M	-189.49M	111.34M	587.69M
Investing Cash Flow	-208.31M	-743.08M	-707.72M	-233.56M	-790.95M
Financing Cash Flow	196.69M	894.49M	496.34M	782.07M	160.61M

Shivalik Rasayan Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 565.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SHIVALIK, the sentiment is Negative. The current price of 565.05 is below the 20-day moving average (MA) of 569.99, above the 50-day MA of 551.66, and below the 200-day MA of 629.22, indicating a bearish trend. The MACD of 2.14 indicates Positive momentum. The RSI at 45.37 is Neutral, neither overbought nor oversold. The STOCH value of 14.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SHIVALIK.

Shivalik Rasayan Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZUARI	73 Outperform	₹15.74B	6.15		―	―	―
SHREEPUSHK	67 Neutral	₹12.99B	22.02		0.38%	16.35%	55.54%
BHAGERIA	64 Neutral	₹7.73B	16.90		0.86%	25.56%	92.57%
SHIVALIK	54 Neutral	₹8.90B	58.86		0.09%	15.29%	25.48%
BODALCHEM	52 Neutral	₹8.73B	29.89		0.17%	25.12%	182.72%
HERANBA	49 Neutral	₹14.60B	473.90		0.34%	―	―
Sector *	44 Neutral	C$923.76M	-8.68	-0.23%	2.69%	24.53%	-41.45%